Shandong Aonai Biopharmaceutical Co., Ltd., a professional pet supplement manufacturer and dog joint supplement specialist based in Linyi City, Shandong Province, China, has announced that its Dutch invention patent application, titled "GASTRIC ACID-RESISTANT DR. KALAN COLLAGEN PEPTIDE AND PREPARATION METHOD THEREFOR" (a gastric acid-resistant Dr.kalan collagen peptide and its preparation method), has been registered and published by the Netherlands Patent Office (Octrooicentrum Nederland) under publication number NL 4000998 A. The patent addresses one of the most stubborn technical challenges in pet joint and bone care: the degradation of collagen peptides by gastric acid.
Application number: 4000998
Filing date: February 10, 2026
Registration date: April 17, 2026
Publication date: April 23, 2026
Applicant: Shandong Aonai Biopharmaceutical Co., Ltd. (No. 2-1, Factory Building, Wenshui Industrial Park, North of National Highway 327, Wenshui Town, Pingyi County, Linyi City, Shandong Province, China)
Inventor: Jianxin Zhang
IPC classification: A23K 50/40, A23K 20/147, A23K 10/26, A23K 40/30, A61K 38/39, A61K 47/38, A61K 47/14, A61K 47/36
Collagen peptides are among the most valued functional ingredients in pet nutrition, prized for their roles in bone and joint repair, skin and coat improvement, and immune support. According to market data, joint health is consistently one of the highest-search-volume categories in pet supplements ― keywords such as dog joint supplement, glucosamine for dogs, canine glucosamine chondroitin, and dog hip and joint supplement attract tens of thousands of searches every month worldwide, reflecting the enormous demand of pet owners seeking effective solutions for arthritis and joint stiffness. However, a persistent technical problem has long frustrated the industry: collagen peptides are easily degraded and deactivated by gastric acid before they can be absorbed. As a result, only a fraction of the functional ingredients actually reaches the bloodstream and tissues, and many joint care products simply fail to deliver their promised benefits. Shandong Aonai's R&D team spent years overcoming this challenge, developing the gastric acid-resistant Dr.kalan collagen peptide technology and filing the patent application in the Netherlands as the cornerstone of its international protection strategy.
The invention provides a gastric acid-resistant Dr.kalan collagen peptide comprising three structural units:
1. Core active ingredient ― pet-derived collagen peptide. The core is a pet-derived collagen peptide with a molecular weight of 1000‒3000 Da. This molecular weight window balances absorption efficiency and biological activity: small enough for efficient intestinal absorption, yet large enough to retain the biofunctions that support cartilage repair and skin regeneration.
2. Gastric acid-resistant protective system ― layered composite coating. This is the core innovation of the invention. Through a unique layered composite coating structure, the collagen peptide is protected by multi-level barriers that maintain an activity retention rate of at least 85% in a gastric acid environment. The functional ingredients pass safely through the stomach and are released and absorbed in the intestinal tract.
3. Functional auxiliary components. These work synergistically with the core ingredient to further strengthen the product's overall health benefits.
4. Precision preparation process. By precisely controlling enzymatic hydrolysis parameters ― enzyme type, temperature, time, and pH ― and systematically optimizing the coating process, the invention ensures both activity and stability, providing a repeatable, standardized manufacturing route for industrial production.
The gastric acid-resistant Dr.kalan collagen peptide integrates three proven efficacies:
Efficacy 1: Promotes bone and joint repair. The small-molecule collagen peptide supplies key amino acid building blocks for cartilage tissue, working synergistically with joint-nutrition staples such as glucosamine and chondroitin to support cartilage repair and skeletal health. It is especially suitable for senior dogs and cats with degenerative joint conditions, high-activity working dogs, and large breeds under heavy joint load ― the core audiences for dog arthritis supplement and senior dog joint supplement products.
Efficacy 2: Improves skin and coat quality. Collagen supplementation strengthens the structural support of the dermis, reducing shedding and improving dry, dull coats so pets display healthy, lustrous fur.
Efficacy 3: Enhances immunity. By improving intestinal barrier function and nutritional supply, the peptide supports the pet's overall immune defense, helping pets cope better with seasonal changes and stress.
This patent publication reflects the company's strength and market insight in three dimensions:
Technology: it solves the industry-wide problem of gastric acid degradation of collagen peptides, establishing a complete technical system of "molecular weight optimization + layered coating + precision enzymatic hydrolysis," providing a reliable path to upgrade the efficacy of pet collagen products;
Products: it provides solid core technology support for the Dr.kalan product family, enabling joint care products with higher absorption rates and stronger efficacy;
Market: as an important node in the European IP system, the Netherlands publication strengthens the company's intellectual property protection for the European and global pet nutrition markets, and offers differentiated partnership value to brands searching for a private label pet supplements partner, a pet joint supplements OEM/ODM factory, or a supplier of glucosamine and chondroitin for dogs.
Shandong Aonai Biopharmaceutical Co., Ltd. is a science-driven pet health enterprise located in the Wenshui Industrial Park, Pingyi County, Linyi City, Shandong Province, China. The company integrates R&D, production, and sales, with a product portfolio spanning dog joint supplements, dog multivitamins, dental care products, and digestive & probiotic supplements under its Dr.kalan brand. As an experienced pet supplement manufacturer and supplier, the company offers flexible OEM/ODM, private label, and custom formula services to brands and distributors worldwide. Its quality assurance system is backed by an FSPCA PCQI-certified R&D team, and the company holds multiple international invention patent applications covering its Dr.kalan compound probiotics and gastric acid-resistant collagen peptides. Committed to "quality first, safety first, technology driven," Shandong Aonai is dedicated to delivering safe, scientific, and premium pet health products to pets and pet parents around the world.
Going forward, Shandong Aonai Biopharmaceutical will continue to deepen its presence in the pet bone and joint health segment, using core patented technologies such as the gastric acid-resistant Dr.kalan collagen peptide as the engine to drive the upgrade of the global pet health industry together with its partners.
EN
